tradingkey.logo

tradingkey.logo
āļ„āđ‰āļ™āļŦāļē


Veracyte Inc

VCYT
āđ€āļžāļīāđˆāļĄāļĨāļ‡āđƒāļ™āļĢāļēāļĒāļāļēāļĢāļ•āļīāļ”āļ•āļēāļĄ
43.820USD
+0.460+1.06%
āļ›āļīāļ” 09-23 16:00ET
3.50BāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
39.29P/E TTM

āđ€āļāļĩāđˆāļĒāļ§āļāļąāļš Veracyte Inc āļšāļĢāļīāļĐāļąāļ—

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.

Veracyte Inc āđ‚āļ›āļĢāđ„āļŸāļĨāđŒ


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™VCYT
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Veracyte Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļOct 30, 2013
āļ‹āļĩāļ­āļĩāđ‚āļ­Stapley (Marc A)
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™824
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Oct 30
āļ—āļĩāđˆāļ­āļĒāļđāđˆ6000 Shoreline Court, Suite 300
āđ€āļĄāļ·āļ­āļ‡SOUTH SAN FRANCISCO
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX - NASDAQ BASIC
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ94080
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ16502436300
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.veracyte.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™VCYT
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļOct 30, 2013
āļ‹āļĩāļ­āļĩāđ‚āļ­Stapley (Marc A)

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ Veracyte Inc


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
133.62K
-6.57%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
133.62K
-6.57%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
133.62K
-6.57%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
48.40K
+10.89%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
48.40K
+10.89%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
48.40K
+10.89%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
47.14K
+11.18%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
47.14K
+11.18%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
47.14K
+11.18%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
33.40K
-5.58%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
133.62K
-6.57%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
133.62K
-6.57%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
133.62K
-6.57%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
48.40K
+10.89%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
48.40K
+10.89%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
48.40K
+10.89%

āļ„āļģāļ–āļēāļĄāļ—āļĩāđˆāļžāļšāļšāđˆāļ­āļĒ

āđƒāļ„āļĢāļ„āļ·āļ­āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Veracyte Inc?


āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļŦāđ‰āļēāļ­āļąāļ™āļ”āļąāļšāđāļĢāļāļ‚āļ­āļ‡ Veracyte Inc āđ„āļ”āđ‰āđāļāđˆ: Mr. Marc A. Stapley

āļĄāļĩāļāļĩāđˆāļŠāļ–āļēāļšāļąāļ™āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ Veracyte Inc (VCYT)?


āļ“ āļ§āļąāļ™āļ—āļĩāđˆ 2026Q1 āļĄāļĩāļŠāļ–āļēāļšāļąāļ™āļˆāļģāļ™āļ§āļ™ 683 āđāļŦāđˆāļ‡āļ—āļĩāđˆāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡ Veracyte Inc āđ‚āļ”āļĒāļĄāļĩāļĄāļđāļĨāļ„āđˆāļēāļĢāļ§āļĄāļ›āļĢāļ°āļĄāļēāļ“ 96.10M āļ„āļīāļ”āđ€āļ›āđ‡āļ™ 120.44% āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļ—āļąāđ‰āļ‡āļŦāļĄāļ” āđ€āļĄāļ·āđˆāļ­āđ€āļ—āļĩāļĒāļšāļāļąāļšāļ§āļąāļ™āļ—āļĩāđˆ 2025Q4 āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™āđ„āļ”āđ‰āđ€āļžāļīāđˆāļĄāļ‚āļķāđ‰āļ™ -1894546.00
tradingkey.logo
āļ„āļģāđ€āļ•āļ·āļ­āļ™āļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡: āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒāđāļĨāļ°āđāļ­āļ›āļžāļĨāļīāđ€āļ„āļŠāļąāļ™āļĄāļ·āļ­āļ–āļ·āļ­āļ‚āļ­āļ‡āđ€āļĢāļēāđƒāļŦāđ‰āļ‚āđ‰āļ­āļĄāļđāļĨāļ—āļąāđˆāļ§āđ„āļ›āđ€āļāļĩāđˆāļĒāļ§āļāļąāļšāļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āļšāļēāļ‡āļ›āļĢāļ°āđ€āļ āļ—āđ€āļ—āđˆāļēāļ™āļąāđ‰āļ™ Finsights āđ„āļĄāđˆāđ„āļ”āđ‰āđƒāļŦāđ‰āļ„āļģāđāļ™āļ°āļ™āļģāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļŦāļĢāļ·āļ­āļāļēāļĢāđāļ™āļ°āļ™āļģāļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āđƒāļ” āđ† āđāļĨāļ°āļāļēāļĢāđƒāļŦāđ‰āļ‚āđ‰āļ­āļĄāļđāļĨāļ”āļąāļ‡āļāļĨāđˆāļēāļ§āđ„āļĄāđˆāļ„āļ§āļĢāļ–āļđāļāļ•āļĩāļ„āļ§āļēāļĄāļ§āđˆāļēāđ€āļ›āđ‡āļ™āļāļēāļĢāđƒāļŦāđ‰āļ„āļģāđāļ™āļ°āļ™āļģāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļŦāļĢāļ·āļ­āļāļēāļĢāđāļ™āļ°āļ™āļģāđ‚āļ”āļĒ Finsights
āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āļĄāļĩāļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡āļ”āđ‰āļēāļ™āļāļēāļĢāļĨāļ‡āļ—āļļāļ™āļ­āļĒāđˆāļēāļ‡āļĄāļēāļ āļĢāļ§āļĄāļ–āļķāļ‡āļāļēāļĢāļŠāļđāļāđ€āļŠāļĩāļĒāđ€āļ‡āļīāļ™āļ•āđ‰āļ™āļ—āļĩāđˆāļĨāļ‡āļ—āļļāļ™āđ„āļ› āđāļĨāļ°āļ­āļēāļˆāđ„āļĄāđˆāđ€āļŦāļĄāļēāļ°āļŠāļģāļŦāļĢāļąāļšāļ—āļļāļāļ„āļ™ āļœāļĨāļāļēāļĢāļ”āļģāđ€āļ™āļīāļ™āļ‡āļēāļ™āđƒāļ™āļ­āļ”āļĩāļ•āļ‚āļ­āļ‡āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļāļēāļĢāļĨāļ‡āļ—āļļāļ™āđ„āļĄāđˆāđ„āļ”āđ‰āļšāđˆāļ‡āļšāļ­āļāļ–āļķāļ‡āļœāļĨāļāļēāļĢāļ”āļģāđ€āļ™āļīāļ™āļ‡āļēāļ™āđƒāļ™āļ­āļ™āļēāļ„āļ•
Finsights āļ­āļēāļˆāļ­āļ™āļļāļāļēāļ•āđƒāļŦāđ‰āļœāļđāđ‰āļĨāļ‡āđ‚āļ†āļĐāļ“āļēāļŦāļĢāļ·āļ­āļžāļąāļ™āļ˜āļĄāļīāļ•āļĢāļšāļļāļ„āļ„āļĨāļ—āļĩāđˆāļŠāļēāļĄāļ§āļēāļ‡āļŦāļĢāļ·āļ­āļŠāđˆāļ‡āđ‚āļ†āļĐāļ“āļēāļšāļ™āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒāļŦāļĢāļ·āļ­āđāļ­āļ›āļžāļĨāļīāđ€āļ„āļŠāļąāļ™āļĄāļ·āļ­āļ–āļ·āļ­āļ‚āļ­āļ‡āđ€āļĢāļēāļŦāļĢāļ·āļ­āļŠāđˆāļ§āļ™āđƒāļ”āļŠāđˆāļ§āļ™āļŦāļ™āļķāđˆāļ‡āļ‚āļ­āļ‡āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒāļŦāļĢāļ·āļ­āđāļ­āļ›āļžāļĨāļīāđ€āļ„āļŠāļąāļ™āļĄāļ·āļ­āļ–āļ·āļ­ āđāļĨāļ°āļ­āļēāļˆāđ„āļ”āđ‰āļĢāļąāļšāļ„āđˆāļēāļ•āļ­āļšāđāļ—āļ™āļˆāļēāļāļāļēāļĢāļ—āļĩāđˆāļ„āļļāļ“āļĄāļĩāļ›āļāļīāļŠāļąāļĄāļžāļąāļ™āļ˜āđŒāļāļąāļšāđ‚āļ†āļĐāļ“āļē
ÂĐ āļĨāļīāļ‚āļŠāļīāļ—āļ˜āļīāđŒ: FINSIGHTS MEDIA PTE. LTD. āļŠāļ‡āļ§āļ™āļĨāļīāļ‚āļŠāļīāļ—āļ˜āļīāđŒāļ—āļļāļāļ›āļĢāļ°āļāļēāļĢ